Informationen på denna sida är avsedd för journalister, press och media. Klicka ja för att komma till nyhetsrummet. Klickar du nej kommer du tillbaka till mynewsdesk.com.
Recombinant Antibodies: Covagen AG presents the Fynomer technology
Speaker: Dr. Simon Brack, Head of Lead Discovery, Covagen AG, Zürich, Switzerland
Topic: Fynomers Neutralizing IL-17A: Making Use of Fc fusion protein
We will present the versatility and broad applicability of the Fynomer technology. As an example, the isolation and characterization of high-affinity Fynomers capable of neutralizing IL-17 will be shown. Furthermore, engineered Fynomer-Fc fusion proteins having appropriate physico-chemical and in vivo half-life properties are attractive drug candidates for pre-clinical and clinical development.
For more info about the event please visit www.informaglobalevents.com/event/antibodies